1Buy.AI | $3,900,000 | (Feb 3, 2026)
PranaX | $17,000,000 | (Feb 3, 2026)
DexMat | $5,000,000 | (Feb 3, 2026)
Certified by Founder
Lodge
Vima Therapeutics
start up
United States
- Cambridge, Massachusetts
- 30/05/2025
- Series A
- $60,000,000
Vima Therapeutics is a clinical-stage biotechnology company pioneering a new era in the treatment of dystonia and related movement disorders.
We are advancing VIM0423, a potential first-in-class oral therapy for dystonia, with the goal of helping individuals regain control of their movements by targeting the underlying cause of the disease.
Vima brings together a team of physicians, scientists, and drug developers with deep expertise in movement disorders and a shared commitment to deliver a meaningful oral therapy for patients.
- Industry Biotechnology Research
- Website https://vimatx.com/
- LinkedIn https://www.linkedin.com/company/vima-therapeutics/
Prenosis | $20,000,000 | (Feb 3, 2026)
CloudForge AI | $3,950,000 | (Feb 3, 2026)
Linq | $20,000,000 | (Feb 3, 2026)
Breezy | $10,000,000 | (Feb 3, 2026)
Poetiq | $45,800,000 | (Feb 3, 2026)
JJG Machining Group | $30,000,000 | (Feb 3, 2026)
Principle | $2,000,000 | (Feb 3, 2026)
BizTrip AI | $1,500,000 | (Feb 3, 2026)
Co-reactive | $7,754,157 | (Jan 30, 2026)